Ced cisplatin resistance have been also revealed in E6-overexpressing TL-10 and C33A cells (Supplementary Figure 2 reduced panel). We consequently suggest that Bcl-2 antagonist could potentially overcome cisplatin resistance mediated by E6-reduced miR-184, and consequently to enhance outcomes in NSCLC sufferers with E6-positive/low-miR-184 tumors.Discovery, Taipei Healthcare University, Taipei, Taiwan) [10]. TL-10 cells were primarily cultured …
Continue reading “Ced cisplatin resistance have been also revealed in”